Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain.
Juan Francisco DelgadoJuan OlivaÁlvaro González FrancoJose Maria CepedaJosé Ángel García-GarcíaAlmudena González-DomínguezAlbert Garcia-CasanovasSilvia Jiménez MerinoJosep Comín ColetPublished in: Journal of medical economics (2020)
FCM results in an annual cost saving of €534.80 per patient, and would thus be expected to reduce the economic burden of CHF in Spain.